Recent advances in the development of vaccines for Ebola virus disease
- PMID: 26596227
- DOI: 10.1016/j.virusres.2015.10.021
Recent advances in the development of vaccines for Ebola virus disease
Abstract
Ebola virus is one of the most dangerous microorganisms in the world causing hemorrhagic fevers in humans and non-human primates. Ebola virus (EBOV) is a zoonotic infection, which emerges and re-emerges in human populations. The 2014 outbreak was caused by the Zaire strain, which has a kill rate of up to 90%, though 40% was recorded in the current outbreak. The 2014 outbreak is larger than all 20 outbreaks that have occurred since 1976, when the virus was first discovered. It is the first time that the virus was sustained in urban centers and spread beyond Africa into Europe and USA. Thus far, over 22,000 cases have been reported with about 50% mortality in one year. There are currently no approved therapeutics and preventive vaccines against Ebola virus disease (EVD). Responding to the devastating effe1cts of the 2014 outbreak and the potential risk of global spread, has spurred research for the development of therapeutics and vaccines. This review is therefore aimed at presenting the progress of vaccine development. Results showed that conventional inactivated vaccines produced from EBOV by heat, formalin or gamma irradiation appear to be ineffective. However, novel vaccines production techniques have emerged leading to the production of candidate vaccines that have been demonstrated to be effective in preclinical trials using small animal and non-human primates (NHP) models. Some of the promising vaccines have undergone phase 1 clinical trials, which demonstrated their safety and immunogenicity. Many of the candidate vaccines are vector based such as Vesicular Stomatitis Virus (VSV), Rabies Virus (RABV), Adenovirus (Ad), Modified Vaccinia Ankara (MVA), Cytomegalovirus (CMV), human parainfluenza virus type 3 (HPIV3) and Venezuelan Equine Encephalitis Virus (VEEV). Other platforms include virus like particle (VLP), DNA and subunit vaccines.
Keywords: Hemorrhagic fever; Pre-existing immunity; Replication competent vaccine; Replication incompetent Vaccine; Zoonotic infections.
Copyright © 2015 Elsevier B.V. All rights reserved.
Similar articles
-
Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.J Virol. 2018 May 14;92(11):e00363-18. doi: 10.1128/JVI.00363-18. Print 2018 Jun 1. J Virol. 2018. PMID: 29514907 Free PMC article.
-
Ebolavirus Vaccines: Progress in the Fight Against Ebola Virus Disease.Cell Physiol Biochem. 2015;37(5):1641-58. doi: 10.1159/000438531. Epub 2015 Nov 5. Cell Physiol Biochem. 2015. PMID: 26535889 Review.
-
Recombinant Modified Vaccinia Virus Ankara Generating Ebola Virus-Like Particles.J Virol. 2017 May 12;91(11):e00343-17. doi: 10.1128/JVI.00343-17. Print 2017 Jun 1. J Virol. 2017. PMID: 28331098 Free PMC article.
-
Ebola vaccine trials: progress in vaccine safety and immunogenicity.Expert Rev Vaccines. 2019 Dec;18(12):1229-1242. doi: 10.1080/14760584.2019.1698952. Expert Rev Vaccines. 2019. PMID: 31779496 Review.
-
A Bivalent, Spherical Virus-Like Particle Vaccine Enhances Breadth of Immune Responses against Pathogenic Ebola Viruses in Rhesus Macaques.J Virol. 2020 Apr 16;94(9):e01884-19. doi: 10.1128/JVI.01884-19. Print 2020 Apr 16. J Virol. 2020. PMID: 32075939 Free PMC article.
Cited by
-
Vesicular Stomatitis Virus Pseudotyped with Ebola Virus Glycoprotein Serves as a Protective, Noninfectious Vaccine against Ebola Virus Challenge in Mice.J Virol. 2017 Aug 10;91(17):e00479-17. doi: 10.1128/JVI.00479-17. Print 2017 Sep 1. J Virol. 2017. PMID: 28615211 Free PMC article.
-
Perspectives towards antiviral drug discovery against Ebola virus.J Med Virol. 2019 Dec;91(12):2029-2048. doi: 10.1002/jmv.25357. Epub 2019 Sep 30. J Med Virol. 2019. PMID: 30431654 Free PMC article. Review.
-
Multifunctional particle-constituted microneedle arrays as cutaneous or mucosal vaccine adjuvant-delivery systems.Hum Vaccin Immunother. 2016 Aug 2;12(8):2075-2089. doi: 10.1080/21645515.2016.1158368. Epub 2016 May 9. Hum Vaccin Immunother. 2016. PMID: 27159879 Free PMC article. Review.
-
Vaccines against Ebola virus and Marburg virus: recent advances and promising candidates.Hum Vaccin Immunother. 2019;15(10):2359-2377. doi: 10.1080/21645515.2019.1651140. Epub 2019 Oct 7. Hum Vaccin Immunother. 2019. PMID: 31589088 Free PMC article. Review.
-
Therapeutic vaccination strategies against EBOV by rVSV-EBOV-GP: the role of innate immunity.Curr Opin Virol. 2021 Dec;51:179-189. doi: 10.1016/j.coviro.2021.10.007. Epub 2021 Nov 5. Curr Opin Virol. 2021. PMID: 34749265 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical